These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1011 related items for PubMed ID: 2438781

  • 1. Advances in chemotherapy for large cell lymphoma.
    Coleman M, Gerstein G, Topilow A, Lebowicz J, Berhardt B, Chiarieri D, Silver RT, Pasmantier MW.
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [Abstract] [Full Text] [Related]

  • 2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    N Engl J Med; 1993 Apr 08; 328(14):1002-6. PubMed ID: 7680764
    [Abstract] [Full Text] [Related]

  • 3. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA.
    Semin Hematol; 1987 Apr 08; 24(2 Suppl 1):21-5. PubMed ID: 2438778
    [Abstract] [Full Text] [Related]

  • 4. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI.
    J Clin Oncol; 1991 Jan 08; 9(1):25-38. PubMed ID: 1702144
    [Abstract] [Full Text] [Related]

  • 5. European experience with ifosfamide in lymphomas.
    von Kalle AK, Schaadt M, Diehl V.
    Semin Oncol; 1989 Feb 08; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI, Longo DL, DeVita VT, Hubbard SM, Miller TP, Young RC.
    Ann Oncol; 1991 Jan 08; 2 Suppl 1():33-5. PubMed ID: 1710487
    [Abstract] [Full Text] [Related]

  • 7. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M.
    J Clin Oncol; 1994 Jul 08; 12(7):1366-74. PubMed ID: 7517442
    [Abstract] [Full Text] [Related]

  • 8. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A.
    N Engl J Med; 1992 Nov 05; 327(19):1342-9. PubMed ID: 1383819
    [Abstract] [Full Text] [Related]

  • 9. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
    Armitage JO.
    Ann Oncol; 1991 Jan 05; 2 Suppl 1():37-41. PubMed ID: 1710488
    [Abstract] [Full Text] [Related]

  • 10. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT, Young RC.
    J Clin Oncol; 1994 Oct 05; 12(10):2153-9. PubMed ID: 7523607
    [Abstract] [Full Text] [Related]

  • 11. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
    Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K, Beshevkin M, Silver RT, Reisman AM, Pasmantier MW.
    Semin Hematol; 1988 Apr 05; 25(2 Suppl 2):23-33. PubMed ID: 2456620
    [Abstract] [Full Text] [Related]

  • 12. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI.
    Semin Hematol; 1988 Apr 05; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [Abstract] [Full Text] [Related]

  • 13. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    Ann Oncol; 1994 Apr 05; 5 Suppl 2():91-5. PubMed ID: 7515652
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI, Andersen J, Colgan J, Glick J, Resnick GD, O'Connell M, Cassileth PA.
    Cancer; 1995 Feb 01; 75(3):865-73. PubMed ID: 7530168
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P.
    J Clin Oncol; 1996 Apr 01; 14(4):1275-81. PubMed ID: 8648384
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.